All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Significant advances in antibody engineering have led to the development of a novel therapeutic class with a unique mechanism of action: to target both malignant cells and T cells and bring them closer together, activating the cytotoxic capacity of the immune cell. T-cell engagers include IgG-like bispecific antibodies and optimized designs without the Fc domain (BiTEs, DARTs, and TriKEs).